Introduction {#sec1}
============

The isoprenoid biosynthetic pathway produces over 60 000 small-molecule metabolites that perform numerous essential functions in all forms of life.^[@ref1]^ A few examples include electron transfer (ubiquinones), cellular membranes (sterols and hopanes), hormones (sterols, sesquiterpenes, diterpenes), pheromones (monoterpenes), photosynthesis (carotenoids and chlorophylls), and signal transduction (isoprenylated proteins). Isoprenoid molecules are synthesized from (*R*)-mevalonate (**MVA**)^[@ref2]^ or [d]{.smallcaps}-methylerythritol phosphate (**MEP**)^[@ref3]^ by two fundamentally different pathways. The **MVA** pathway provides isopentenyl diphosphate (**IPP**) and dimethylallyl diphosphate (**DMAPP**) for isoprenoid biosynthesis in most Eukarya, including all mammals and the cytosol and mitochondria in plants, Archaea, and a few Bacteria. **IPP** and **DMAPP** are synthesized from **MEP** in most Bacteria and Apicomplexa, a group of parasitic protists.

**MEP** is synthesized in two steps from pyruvate and [d]{.smallcaps}-glyceraldehyde phosphate via [d]{.smallcaps}-deoxyxylulose phosphate catalyzed by deoxyxylulose phosphate synthase (DXS) and deoxyxylulose keto-reductase (DXR or IspC), respectively.^[@ref3]^**MEP** is converted to cyclic methylerythritol diphosphate (**cMEDP**) in three steps catalyzed by diphosphocytidylmethylerythritol (**CDP-ME**) synthase (IspD), diphosphocytidylmethylerythrityl phosphate (**CDP-MEP**) synthase (IspE), and cyclomethylerythrityl diphosphate (**cMEDP**) synthase (IspF). Subsequently, the cyclic diphosphate is opened reductively by hydroxydimethylallyl diphosphate (**HDMAPP**) synthase (IspG), and the hydroxyl group is removed by a second reduction by IspH to give a mixture of **IPP** and **DMAPP**.^[@ref3]^ The steps between **MEP** and **IPP**/**DMAPP** and the genes encoding the biosynthetic enzymes are shown in Scheme [1](#sch1){ref-type="scheme"}.

![Biosynthesis of **IPP** and **DMAPP** from **MEP**](jo-2014-01529k_0006){#sch1}

The *ispD*, *ispE*, and *ispF* genes encode monofunctional enzymes in most **MEP**-dependent organisms. However, there are several reports of fused *ispD* and *ispF* that encode bifunctional IspDF proteins in bacteria, including several genera of α-proteobacteria belonging to the order Rhizobiales.^[@ref4]^ The IspDF protein catalyzes the first and last steps in the conversion of **MEP** to **cMEDP**, and the missing ispE activity can be provided in vivo with an enzyme from the same or different organisms. Time course studies with IspDF and IspE from *Agrobacterium tumefacians* indicate that the enzymes in combination efficiently convert **MEP** to **cMEDP** without any evidence for substrate channeling between the individual active sites in the protein complex.^[@ref5]^

Since the **MEP** pathway is orthogonal to the **MVA** pathway, it is an attractive target for development of small-molecule inhibitors as antibacterial, antiparasitic, and herbicidal agents.^[@ref6]^ Most of the reports of inhibitors and alternate substrates are for the DXS,^[@ref7]^ DXR,^[@ref8]^ IspD,^[@ref9],[@ref10]^ IspG,^[@ref11]^ and IspH^[@ref9]^ proteins found in the early and later parts of the pathway. In a recent report, high throughput screening identified a triazolopyrimidine inhibitor of IspD, and subsequent synthetic work provided structurally related submicromolar inhibitors with herbicidal activity.^[@ref12]^

Studies with DXR^[@ref13]^ indicate that the enzyme accepts a number of analogues as alternate substrates and synthesizes products that are potentially inhibitors of downstream enzymes. We now report the synthesis of five analogues of **MEP** and showed that four of these molecules and their products are alternate substrates for the three consecutive reactions catalyzed by *Agrobacterium tumefaciens* IspDF and IspE.

Results and Discussion {#sec2}
======================

Synthesis of MEP Analogues {#sec2.1}
--------------------------

Five **MEP** analogues, [d]{.smallcaps}-erythritol phosphate (**EP**), [d]{.smallcaps}-methylthreitol phosphate (**MTP**), [d]{.smallcaps}-ethylerythritol phosphate (**EEP**), [d]{.smallcaps}-aminodeoxymethylerythritol phosphate (**NMEP**), and [d]{.smallcaps}-methylerythritol thiophosphate (**MESP**), were synthesized for this study (Figure [1](#fig1){ref-type="fig"}). **EP** and **EEP** were synthesized from 1,3-*O*-benzylidene-[d]{.smallcaps}-erythrulose and 4-(*t*-butyldimethylsilyl) ether (**1**) by the dioxanone approach outlined in Scheme [2](#sch2){ref-type="scheme"}.^[@ref14]^ The five-step route to **MTP** was described previously.^[@ref14]^

![**MEP** analogues.](jo-2014-01529k_0001){#fig1}

![Synthesis of **EP** and **EEP**](jo-2014-01529k_0007){#sch2}

The route to **EP** from dioxanone **1** is shown in Scheme [2](#sch2){ref-type="scheme"}. Reduction of **1** with NaBH~4~ in methanol, followed by desilylation with tetrabutylammonium fluoride, gave diol **3** with NMR spectral data in accord with the literature.^[@ref15]^ Phosphorylation of the primary hydroxyl group with dibenzyl chlorophosphate in pyridine and hydrogenolysis of the benzyl and benzylidene protecting groups gave **EP**, whose NMR parameters matched the reported values.^[@ref10]^

**EEP** was prepared by a similar set of reactions. Treatment of ketone **1** with ethylmagnesium bromide proceeded with highly stereoselective axial-face addition to the carbonyl group. Previously, an "axial"/"equatorial" stereoselectivity of 20:1 was seen for the related addition of methylmagnesium bromide.^[@ref14]^ Desilylation with Bu~4~NF gave diol **6**. The diol was lithiated with *n*-butyllithium and phosphorylated regioselectively at the primary hydroxyl group with freshly prepared dibenzyl chlorophosphate. Catalytic hydrogenolysis of the dibenzyl phosphate and benzylidene ring gave **EEP**.

**NMEP** was synthesized from (*Z*)-4-(*tert*-butyldimethylsilanyloxy)-3-methyl-but-2-en-1-ol (**8**)^[@ref16]^ (Scheme [3](#sch3){ref-type="scheme"}). Our original strategy involved phosphorylation of **8** using the benzyl phosphite-iodine procedure,^[@ref17]^ removal of the TBDMS group, and introduction of the amino group by a Mitsunobu displacement^[@ref18]^ with phthalimide, followed by hydrolysis of the imide. However, our attempts to hydrolyze the phthalimide group prior to a Sharpless dihydroxylation^[@ref19]^ failed, presumably because of the reactivity of the phosphate triester. Alcohol **8** was then protected as a THP ether; the TBDMS protecting group was removed; and nitrogen was introduced at C1 by a Mitsunobu displacement.^[@ref17]^ The phthalimide moiety was removed with hydrazine, and the resulting amine was protected as a Boc amide. The THP blocking group was removed, and alcohol **14** was phosphorylated using benzyl phosphite-iodine.^[@ref17]^ A Sharpless dihydroxylation^[@ref19]^ gave **16** as a 12:1 mixture of 2*R*,3*S* and 2*S*,3*R* enantiomers, as judged by chiral HPLC. **NMEP** was obtained after removing the benzyl and Boc protecting groups.

![Synthesis of **NMEP**](jo-2014-01529k_0008){#sch3}

The synthesis of **MESP** is outlined in Scheme [4](#sch4){ref-type="scheme"}. Ester **17**([@ref16]) was asymmetrically dihydroxylated as described for **15**.^[@ref19]^ Diol **18** was first protected as an orthoester. Although the reaction proceeded in high yield as judged from an NMR spectrum of the crude product, the orthoester was unstable on a silica column and was isolated in 51% yield. Reduction of the methyl ester with LiBH~4~ proceeded in excellent yield (NMR), but again the resulting alcohol was unstable on silica and was obtained in 61% yield after purification. To improve yields, we omitted purification steps for reactions 2 and 3, and pure tosylated orthoester (steps 2--4) was obtained in an overall 89% yield. The orthoester protecting group was removed in two steps by a mild treatment with aq. HCl to give a formate ester, followed by hydrolysis with ammonia in CH~3~OH to give diol tosylate **22**. Treatment of **22** with *t*BuOK and removal of the silyl blocking group gave epoxide **24**, which was opened with inorganic thiophosphate to give **MESP**. An NMR analysis of the C1 Mosher's ester of diol **24** indicated a 17:1 ratio of 2*S*,3*R* and 2*R*,3*S* enantiomers.^[@ref20]^

![Synthesis of **MESP**](jo-2014-01529k_0009){#sch4}

Evaluation of **EP**, **MTP**, and **EEP** as Alternate Substrates for IspDF and IspE {#sec2.2}
-------------------------------------------------------------------------------------

**EP**, **MTP**, and **EEP**, along with **MEP** as a control, were incubated with different combinations of \[α-^32^P\]**CTP**, \[γ-^32^P\]**ATP**, IspDF, and IspE. The labeling patterns expected from these experiments are shown in Scheme [5](#sch5){ref-type="scheme"}. The reaction mixtures were analyzed by TLC,^[@ref4],[@ref5]^ and the results are shown in Figure [2](#fig2){ref-type="fig"}.

![Predicted Pattern for Incorporation of ^32^P into the Products from Incubations with IspDF and IspE](jo-2014-01529k_0010){#sch5}

Incubation of IspDF with **MEP** and \[α-^32^P\]**CTP** gave **CDP-ME** as the only radioactive product, as expected for catalysis by the IspD active site in the IspDF fusion protein^[@ref4]^ (see lane 3). A similar incubation with IspDF and IspE with **MEP**, \[α-^32^P\]**CTP**, and \[γ-^32^P\]**ATP** gave two ^32^P-labeled products, **cMEDP** (radiolabel from \[γ-^32^P\]ATP) and **CMP** (radiolabel from \[α-^32^P\]**CTP**) (see lane 4).^[@ref4]^ A spot with a smaller *R*~f~ in the region expected for **CDP-MEP** was not seen.

Related incubations with **EP** indicated that IspDF gave **CDP-E** (lane 5) and IspDF/IspE gave **cEDP** and **CMP** (lane 6), although the reactions appeared to be slower and a spot was seen for **CDP-E**. The TLC profiles for **EEP** suggest that **CDP-EE** and **CMP** have similar *R*~f~ values. Incubation of IspDF with **EEP** and \[α-^32^P\]**CTP** (lane 9) gives a single spot as expected for formation of labeled **CDP-EE**. While a similar incubation with IspDF/IspE with **EEP**, \[α-^32^P\]**CTP**, and \[γ-^32^P\]**ATP** gives two spots, as expected, however the spot assigned to **cEEDP** has the same *R*~f~ value as **CMP** (lane 10). No spots were seen with expected *R*~f~ values for **CDP-EP** or **CDP-EEP**.

![TLC plate showing the different products following 1 h incubations with **MEP**, **EP**, **MTP**, or **EEP** (500 μM) with IspDF (4.8 μM) and \[α-^32^P\]**CTP** (150 μM, 40 μCi/μmol) or IspDF, IspE (6.2 μM), \[γ-^32^P\]**ATP** (150 μM, 320 μCi/μmol), and \[α-^32^P\]**CTP** (150 μM, 40 μCi/μmol). The reactions were quenched with methanol. Lane 1: **MEP**, **CTP** (control); lane 2: **MEP**, **ATP** (control); lane 3: **MEP**, IspDF, **CTP**; lane 4: **MEP**, IspDF, IspE, **ATP**, **CTP**; lane 5: **EP**, IspDF, **CTP**; lane 6: **EP**, IspDF, IspE, **ATP**, **CTP**; lane 7: **MTP**, IspDF, **CTP**; lane 8: **MTP**, IspDF, IspE, **ATP**, **CTP**; lane 9: **EEP**, IspDF, **CTP**; lane 10: **EEP**, IspDF, IspE, **ATP**, **CTP**.](jo-2014-01529k_0002){#fig2}

The formation of **CDP-EE** was established by a series of incubations with **EEP** and different combinations of labeled and unlabeled **ATP** and **CTP** (Figure [3](#fig3){ref-type="fig"}). To provide a basis for comparison, we incubated **MEP** with IspDF, IspE, \[α-^32^P\]**CTP**, and \[γ-^32^P\]**ATP**, which resulted in well-resolved spots for **CMP** and **cMEDP** (lane 7), while incubation with IspDF and \[α-^32^P\]**CTP** gave **CDP-ME** with an *R*~f~ distinctive from those of **CMP** and **cMEDP** (lane 8). Similar experiments with **EEP**, visualized in lanes 3 and 1, respectively, show similar patterns, except that the putative spot for **CDP-EE** has the same *R*~f~ value as **CMP**. Overlapping *R*~f~'s for **CDP-EE** and **CMP** were established by the experiments visualized in lanes 2, 4, and 5. In lane 2, **EEP** was incubated with IspDF, \[α-^32^P\]**CTP**, and \[γ-^32^P\]**ATP** to give \[^32^P\]**CDP-EE**, with the same *R*~f~ for \[^32^P\]**CMP** from incubation of **EEP** with IspDF, IspE, \[α-^32^P\]**CTP**, and **ATP** seen in lane 4. The spot for \[^32^P\]**CMP** is absent when **EEP** is incubated with IspDF, IspE, unlabeled **CTP**, and \[γ-^32^P\]**ATP** (lane 5), establishing that **CMP** and **CDP-EE** comigrate. Thus, our TLC studies indicate that the alternate substrates **EP** and **EEP** behave similar to **MEP**([@ref5]) for the three consecutive reactions catalyzed by IspDF and IspE. No clear evidence was seen for the mandatory **CDP-EP** and **CDP-EEP**, although spots indicative of the intermediates were seen at the leading edge for the spot for **ATP** in time course experiments (also see Figures S1 and S2, [Supporting Information](#notes-5){ref-type="notes"}). Difficulty in detecting **CDP-EP** and **CDP-EEP** is not surprising. **CDP-MEP** migrates at a poorly defined spot at the leading edge of that for **ATP** and only constitutes a maximum of ∼10% of the total radioactivity during time course measurements.

![TLC plate showing the different products following 1 h incubations of different combinations of **MEP** and **EEP** (500 μM), IspDF (4.8 μM), IspE (6.2 μM), unlabeled **ATP**, \[γ-^32^P\]**ATP** (150 μM, 320 μCi/μmol), unlabeled **CTP**, and \[α-^32^P\]CTP (150 μM, 40 μCi/μmol). The reactions were quenched with methanol. Lane 1: **EEP**, \[α-^32^P\]**CTP**, IspDF; lane 2: **EEP**, \[α-^32^P\]**CTP**, \[γ-^32^P\]**ATP**, IspDF; lane 3: **EEP**, \[α-^32^P\]**CTP**, \[γ-^32^P\]**ATP**, IspDF, IspE; lane 4: **EEP**, \[α-^32^P\]**CTP**, **ATP**, IspDF, IspE; lane 5: **EEP**, **CTP**, \[γ-^32^P\]**ATP**, IspDF, IspE; lane 6: **EEP**, \[γ-^32^P\]**ATP**, IspDF; lane 7: **MEP**, \[α-^32^P\]**CTP**, \[γ-^32^P\]**ATP**, IspDF, IspE; lane 8: MEP, \[α-^32^P\]**CTP**, IspDF; lane 9: EEP, \[γ-^32^P\]**ATP**; lane 10: EEP, \[α-^32^P\]**CTP**.](jo-2014-01529k_0003){#fig3}

Negative-ion LC--MS analyses of incubation mixtures similar to those described in Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} were performed using single ion monitoring, as previously described for **MEP**.^[@ref4],[@ref5]^ They support the assignments for the products from incubations with **EP** or **EEP**. The reaction mixture from incubation of **EP** with **CTP** and IspDF gave a peak at *m*/*z* 506 and expected for **CDP-E** (Figure [4](#fig4){ref-type="fig"}A). A similar analysis of the incubation of **EP** with **CTP**, **ATP**, IspDF, and IspE gave peaks *m*/*z* 263 for **cEDP** (Figure [4](#fig4){ref-type="fig"}B) and *m*/*z* 322 for **CMP** (data not shown). Related incubations with **EEP** gave peaks at *m*/*z* 534 for **CDP-EE** (Figure [4](#fig4){ref-type="fig"}C), *m*/*z* 291 for **cEEDP** (part D), and *m*/*z* 322 for **CMP** (data not shown).

![LC--MS chromatograms of products detected by single-ion monitoring of products from the following incubations: (A) **EP**, **CTP**, IspDF; (B) **EP**, **CTP**, **ATP**, IspDF, IspE; (C) same as A with **EEP** as a substrate; (D) same as B with **EEP** as a substrate.](jo-2014-01529k_0004){#fig4}

In contrast to **EP** and **EEP**, **MTP** was not a substrate for IspD (Figure [2](#fig2){ref-type="fig"}). In addition, **MTP** at concentrations up to 5 mM did not inhibit turnover of **MEP**. Thus, it appears that the threitol diastereomer is not recognized by the active site of IspD.

Evaluation of **NMEP** and **MESP** as Alternate Substrates for **IspDF** and **IspE** {#sec2.3}
--------------------------------------------------------------------------------------

**MEP** and **NMEP** were incubated with IspDF, IspE, \[α-^32^P\]**CTP**, and \[γ-^32^P\]**ATP** under conditions similar to those shown in Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}. TLC analysis of the products from **MEP**([@ref5]) showed the expected pattern of spots (Figure S3, [Supporting Information](#notes-5){ref-type="notes"}, lanes 1 and 2). TLC analysis of a similar experiment with **NMEP** showed the formation of new radioactive materials with smaller *R*~f~'s than seen for the corresponding **MEP** derivatives that were not resolved into individual peaks (Figure S3, [Supporting Information](#notes-5){ref-type="notes"}, lane 4). Related experiments with **MEP** where IspDF was replaced with H281S, a mutant which does not have IspF activity, gave spots for **CDP-ME** and **CDP-MEP** but not **cMEDP**, as expected (Figure S3, [Supporting Information](#notes-5){ref-type="notes"}, lane 3). A related incubation of **NMEP** with \[H281S\]IspDF and IspE (Figure S3, [Supporting Information](#notes-5){ref-type="notes"}, lane 6) and with \[H281S\]IspDF (Figure S3, [Supporting Information](#notes-5){ref-type="notes"}, lane 5) again gave unresolved spots at lower *R*~f~'s. The product mixtures were then analyzed by negative ion LC--MS. Selective ion monitoring at *m*/*z* 519 (**CDP-NME**), *m*/*z* 599 (**CDP-NMEDP**), and *m*/*z* 276 (**cNMEDP**) gave major peaks at 9.02 min (**CDP-NME**), 37.06 min (**CDP-NMEDP**), and 9.37 min (**cNMEDP**) (Figures S4 and S5, [Supporting Information](#notes-5){ref-type="notes"}).

Similar experiments were performed for **MESP**. In this case, TLC analysis of the products from an incubation with IspDF, IspE, \[α-^32^P\]**CTP**, and \[γ-^32^P\]**ATP** gave spots for c**MESDP** and **CMP** (Figure [5](#fig5){ref-type="fig"}, lane 1). The *R*~f~ of **CDP-MES** was established by incubating **MESP** with \[^32^P\]**CTP**, \[^32^P\]**ATP**, and \[H281S\]IspDF, which only catalyzes the conversion of **MESP** to **CDP-MES** (lane 2), while those for **cMESDP** and **CMP** were established by comparing an incubation with \[α-^32^P\]**CMP** and \[γ-^32^P\]**ATP** (lane 1) with an incubation with \[α-^32^P\]**CMP** and unlabeled **ATP** (lane 3). LC--MS analyses gave negative ion electrospray spectra for **CDP-MES** (*m*/*z* at 536), **CDP-MESP** (*m*/*z* at 616), and **cMESDP** (*m*/*z* 293).

![TLC plate showing the different products formed following a 1 h incubation of **MESP** (500 μM), IspDF (4.8 μM), or \[H281S\]IspDF, IspE (6.2 μM), unlabeled **ATP** or \[γ-^32^P\]**ATP** (150 μM, 320 μCi/μmol), and \[α-^32^P\]**CTP** (150 μM, 40 μCi/μmol). The reactions were quenched with methanol. Lane 1: **MESP**, \[^32^P\]**CTP**, \[^32^P\]**ATP**, IspDF, IspE; lane 2: **MESP**, \[^32^P\]**CTP**, \[^32^P\]**ATP**, \[H281S\]IspDF; lane 3: **MESP**, \[^32^P\]**CTP**, **ATP**, IspDF, IspE.](jo-2014-01529k_0005){#fig5}

Conclusions {#sec2.4}
-----------

Five MEP analogues were synthesized in this study. Four of these and their products were substrates for the three consecutive reactions catalyzed by IspDF and IspE. **EP**, **EEP**, **NMEP**, and **MESP** have topologies that are modestly different from that of **MEP**. In **EP** and **EEP**, a hydrogen atom and an ethyl group, respectively, replace the methyl group at C3 in **MEP**, and both analogues are converted to the corresponding cyclic diphosphates by ispDF and ispE. From a topological perspective, **cEDP** and its subsequent metabolites are likely alternate substrates for IspG and IspH. However, the resulting nor-analogues of **IPP** and **DMAPP** would be unreactive competitive inhibitors of **IPP** isomerase and farnesyl diphosphate (**FPP**) synthase, the next two enzymes in the isoprenoid pathway.^[@ref21],[@ref22]^ In contrast, **EEP** would give ethyl analogues of **IPP** and **DMAPP**, which in turn are substrates for **IPP** isomerase and farnesyl diphosphate (**FPP**) synthase.^[@ref22]^ Related reactions are used to construct the carbon skeletons of insect juvenile hormones.^[@ref23]^**MTP**, the threo diastereomer of **MEP**, is not a substrate for ispD and does not inhibit the enzyme. Conversion of **cNMEDP** to the amino analogue of **HDMAPP** by IspG would produce a potent nanomolar inhibitor of IspH.^[@ref24]^**cMESDP** contains a highly conservative replacement of oxygen by sulfur that should not substantially impede its conversion to the thiolo analogue of **DMAPP**, at which point it becomes a low micromolar inhibitor of **FPP** synthase.^[@ref25]^ Thus, the ability of IspDF and IspE to process analogues of **MEP** presents an opportunity for in vivo synthesis of inhibitors of downstream enzymes and new metabolites.

Experimental Section {#sec3}
====================

Mass analyzers used for HRMS were TOF (pure samples) or Quad/TOF (HPLC/MS).

Synthesis of Alternate Substrates {#sec3.1}
---------------------------------

### 1,3-Benzylidene-[d]{.smallcaps}-erythritol, 4-(*t*-Butyldimethylsilyl) Ether (**2**) {#sec3.1.1}

A solution of dioxanone **1** (2.17 g, 6.73 mmol)^[@ref14]^ in MeOH (22 mL) was stirred and cooled at 0 °C as NaBH~4~ (305 mg, 8.08 mmol) was added portionwise over 10 min. The cooling bath was removed, and the reaction mixture was allowed to stir 1 h at rt. The reaction was neutralized by the addition of satd. NH~4~Cl (10 mL) and H~2~O (10 mL). The aqueous reaction mixture was extracted with CH~2~Cl~2~ (2 × 100 mL). The organic extracts were combined, dried (MgSO~4~), and evaporated to give 2.03 g of crude oil that was an 8:1 mixture (^1^H NMR) of monosilyl ether **2** and starting material. Column purification (EtOAc:hexane 21:79) gave two fractions. After solvent was removed, the first contained 0.58 g of colorless oil that was a mixture of alcohol **2** (∼40%) and dioxanone **1** (∼40%), based on ^1^H NMR analysis, and the second contained 1.18 g of **2** (60%, Corr. for Rec. SM) as a colorless oil: TLC *R*~f~ = 0.68 (50:50, EtOAc:hexane); \[α\]~D~ = 32.5 (*c* = 1.0 in MeOH); ^1^H NMR (500 MHz, C~6~D~6~) δ −0.01 (s, 6H), 0.89 (s, 9H), 2.45 (d, 1H, *J* = 2.8 Hz, OH, Exch. D~2~O), 3.46 (t, 1H, *J* = 10.5 Hz), 3.53 (ddd, 1H, *J* = 9.0, 6.2, 5.1 Hz), 3.77--3.82 (m, 2H), 3.89 (dd, 1H, *J* = 10.5, 4.8 Hz), 4.22 (dd, 1H, *J* = 10.7, 5.4 Hz), 5.31 (s, 1H), 7.10 (t, 1H, *J* = 7.4 Hz), 7.18 (t, 2H, *J* = 7.6 Hz), 7.61 (d, 2H, *J* = 7.5 Hz); ^13^C NMR (126 MHz, C~6~D~6~) δ −5.5, 18.3, 25.9, 65.3, 65.5, 71.0, 80.6, 101.2, 126.7, 128.9, 138.7; IR 3456 (OH), 2930, 2857, 1463, 1254, 1089, 837. No physical data were reported for this known compound.^[@ref26]^ However, the physical data were similar to those reported by Fukumoto^[@ref27]^ for the enantiomer (^1^H NMR, CDCl~3~).

### 1,3-Benzylidene-[d]{.smallcaps}-erythritol (**3**) {#sec3.1.2}

A solution of silyl ether **2** (0.97 g, 2.99 mmol) in THF (5 mL) was stirred and cooled at 0 °C as 1.0 M Bu~4~NF (3.3 mL, 3.29 mmol) was added dropwise over 2 min. The cooling bath was removed, and the reaction mixture was allowed to stir at room temperature for 15 min. The reaction solution was diluted with H~2~O (5 mL) and Et~2~O (70 mL). Following extraction of the aqueous layer with Et~2~O (70 mL), the ethereal layers were combined, dried (MgSO~4~), and evaporated to give 1.67 g of an oil. Column purification (EtOAc:hexane 70:30) gave 0.50 g (79%) of a white solid: TLC *R*~f~ = 0.47 (EtOAc); ^1^H NMR (500 MHz, C~5~H~5~N) δ 3.95 (t, 1H, *J* = 10.4 Hz), 4.15 (ddd, 1H, *J* = 9.4, 5.4, 1.7 Hz), 4.33--4.39 (m, 2H), 4.49 (d, 1H, *J* = 11.8 Hz), 4.59 (dd, 1H, *J* = 10.7, 5.4 Hz), 5.82 (s, 1H), 6.69 (br s, 1H, OH, Exch. D~2~O), 7.22 (d, 1H, *J* = 5.8 Hz), 7.36 (m, 2H), 7.74 (m, 2H); ^13^C NMR (126 MHz, C~5~H~5~N) δ 61.9, 62.3, 72.3, 84.9, 101.5, 127.2, 128.4, 129.0, 139.5. The NMR data agree with those reported by Pinto in the literature (^1^H NMR CD~3~OD).^[@ref15]^

### 1,3-*O*-Benzylidene-[d]{.smallcaps}-erythritol 4-Dibenzylphosphate (**4**) {#sec3.1.3}

The phosphorylation was carried out as described by MacDonald et al.^[@ref28]^ A solution of dibenzyl chlorophosphate was prepared by stirring a mixture of *N*-chlorosuccinimide (76 mg, 0.57 mmol) and dibenzyl phosphite (150 mg, 0.57 mmol) in benzene (2 mL) at room temperature for 1 h. The precipitate was separated by centrifugation and the supernatant added to a solution of 1,3-*O*-benzylidene-[d]{.smallcaps}-erythritol **3** (100 mg, 0.48 mmol) in dry pyridine (4 mL) at 0 °C. The resultant solution was stirred for 24 h at 0 °C and 24 h at room temperature. Another portion of freshly prepared dibenzyl chlorophosphate (0.57 mmol) in benzene (1 mL) was added, and stirring was continued for 48 h. The reaction was quenched with ice (∼1 g), and volatiles were removed under reduced pressure. The residue was diluted with water (30 mL) and extracted with DCM (3 × 30 mL). The combined organic layers were dried over Na~2~SO~4~, and the solvent was evaporated. Purification of the residue by chromatography (silica gel benzene/ethyl acetate 1:1) yielded 26 mg of a 1:1 mixture of **4** (18 mg, ca. 8%) and starting material (8 mg) and 27.4 mg (12%) of **4** as a colorless oil: TLC *R*~f~ 0.24 (hexane/ethyl acetate 4:6), 0.26 (benzene/ethyl acetate 1:1); ^1^H NMR (500 MHz, C~6~D~6~) δ 3.6 (t, 2H, *J* = 10.5 Hz), 4.01 (br, 1H), 4.30 (t, 1H, *J* = 10.5 Hz), 4.35 (dd, 1H, *J* = 5.4, 10.5 Hz), 4.47 (m, 1H), 4.74 (br s, 1H), 4.81--4.93 (m, 4H), 5.31 (s, 1H), 6.99--7.18 (m, 13H), 7.59 (m, 2H); ^13^C NMR (126 MHz, C~6~D~6~) δ 29.2, 61.4, 67.1, 69.8, 71.3, 81.6, 101.4, 126.8, 136.1, 138.6; ^31^P NMR (202 MHz, C~6~D~6~) δ 1.35.

### [d]{.smallcaps}-Erythritol 4-Phosphate, Ammonium Salt (**EP**) {#sec3.1.4}

Deprotection of the dibenzyl phosphate (**4**, 24 mg, 0.05 mmol) was accomplished by hydrogenation using 20% Pd(OH)~2~/C (12 mg) in MeOH (3 mL) with magnetic stirring at 1 atm of H~2~ for 24 h. The catalyst was filtered off, and the solvent was evaporated. The residue was dissolved in water (3 mL) followed by dropwise addition of 10% NH~4~OH (1 mL). Lyophilization gave 12 mg (100%) of a flocculent amorphous solid: TLC *R*~f~ 0.2 (acetonitrile/isopropyl alcohol/10% aq. NH~4~OH 1:1:1); ^1^H NMR (500 MHz, D~2~O) δ 3.62 (dd, 1H, *J* = 6.9, 11.4 Hz), 3.67 (br, 1H), 3.74 (br t, 1H, *J* = 6.9 Hz), 3.81 (d, 1H, *J* = 6.2), 3.90 (br, 2H); ^13^C NMR (126 MHz, D~2~O) δ 32.3, 65.5, 67.5, 74.1; ^31^P NMR (202 MHz, D~2~O) δ 5.36. The data agree with those reported by Lillo et al.^[@ref10]^

### 1,3-*O*-Benzylidene-2-*C*-ethyl-[d]{.smallcaps}-erythritol 4-(*t*-butyldimethylsilyl) Ether (**5**) {#sec3.1.5}

A solution of 1,3-*O*-benzylidene-[d]{.smallcaps}-erythrulose and 4-(*t*-butyldimethylsilyl) ether (**1**, 900 mg, 2.79 mmol)^[@ref14]^ in dry ether (20 mL) was stirred and cooled at −78 °C as EtMgBr (1.4 mL, 4.2 mmol, 3 M in Et~2~O) was added dropwise. After 45 min, the reaction was quenched with MeOH (5 mL) and allowed to warm to room temperature. Satd. aq. NH~4~Cl (15 mL) and water (15 mL) were added, and the product was extracted with ether (3 × 30 mL). The combined organic layers were washed with satd. NaHCO~3~, dried (MgSO~4~), and evaporated to give 1.1 g of crude material. Purification by flash chromatography (silica gel, hexane/ethyl acetate 95:5) afforded 810 mg (82%) of a viscous colorless oil: TLC *R*~f~ 0.42 (hexane/ethyl acetate 8:2); ^1^H NMR (500 MHz, C~6~D~6~) δ −0.044 (s, 3H), −0.036 (s, 3H), 0.86 (s, 9H), 1.10 (t, 3H, *J* = 7.5 Hz), 1.60 (app sextet, 1H, *J* = 7.5 Hz), 2.24 (app sextet, 1H, *J* = 7.5 Hz), 2.86 (s, 1H), 3.46 (d, 1H, *J* = 11 Hz), 3.78 (dd, 1H, *J* = 7.8, 4.0 Hz), 3.87 (m, 2H), 4.26 (d, 1H, *J* = 11 Hz), 5.40 (s, 1H), 7.11--7.20 (m, 3H), 7.60 (m, 2H); ^13^C NMR (126 MHz, C~6~D~6~) δ −5.8, −5.7, 18.1, 24.0, 25.8, 63.0, 68.1, 72.2, 82.2, 102.0, 126.7, 128.5, 128.9, 138.8.

### 1,3-*O*-Benzylidene-2-*C*-ethyl-[d]{.smallcaps}-erythritol (**6**) {#sec3.1.6}

A solution of silyl ether **5** (780 mg, 2.21 mmol) in anhydrous THF (8 mL) was stirred at 0 °C as Bu~4~NF (2.7 mL, 1 M in THF) was added. After 15 min at room temperature, H~2~O (5 mL) was added; the product was extracted with ether (80 mL); and the ethereal extracts was dried (MgSO~4~) and evaporated. Purification by flash chromatography (silica gel, hexane/ethyl acetate 4:6) afforded 486 mg (92%) of a viscous oil: TLC *R*~f~ 0.24 (hexane/ethyl acetate 4:6); ^1^H NMR (500 MHz, C~6~D~6~) δ 0.92 (t, 3H, *J* = 7.5 Hz), 1.35 (app sextet, 1H, *J* = 7.5 Hz), 2.09 (app sextet, 1H, *J* = 7.5 Hz), 3.25 (d, 1H, *J* = 11 Hz), 3.58 (dd, 1 H, *J* = 6.5, 10.4 Hz), 3.67 (t, 1H, *J* = 6.5 Hz), 3.73 (dd, 1H, *J* = 5.9, 10.4 Hz), 4.08 (d, 1H, *J* = 11 Hz), 5.34 (s, 1H), 7.10--7.19 (m, 13H), 7.54 (m, 2H); ^13^C NMR (126 MHz, C~6~D~6~) δ 23.8, 61.4, 67.7, 72.3, 83.9, 102.1, 126.8, 138.7.

### 1,3-*O*-Benzylidene-2-*C*-ethyl-[d]{.smallcaps}-erythritol 4-Dibenzylphosphate (**7**) {#sec3.1.7}

A solution of diol **6** (245 mg, 1.03 mmol) in THF (7 mL) was stirred and cooled at −78 °C as an aliquot of 1.6 M BuLi in hexane (0.96 mL, 1.54 mmol) was added dropwise. After 5 min, a solution of dibenzyl chlorophosphate (1.54 mmol; freshly prepared from dibenzyl phosphite) in benzene (5 mL) prepared as described for **4** was added. Stirring was continued for 10 min at −78 °C and 15 min at room temp. Ether (60 mL) and water (2 mL) were added, and the ethereal layer was dried (MgSO~4~) and evaporated to give 520 mg of crude product. Purification by flash chromatography (silica gel, hexane/ethyl acetate 4:6) afforded 450 mg (88%) of an oil (**14**): TLC *R*~f~ 0.3 (hexane/ethyl acetate 4:6); ^1^H NMR (500 MHz, C~6~D~6~) δ 0.99 (t, 3H, *J* = 7.5 Hz), 1.37 (app sextet, 1H, *J* = 7.5 Hz), 2.14 (app sextet, 1H, *J* = 7.5 Hz), 3.55 (d, 1H, *J* = 11 Hz), 4.16 (s, 1 H), 4.26 (d, 1H, *J* = 11 Hz), 4.25--4.33 (m, 1H), 4.89 (d, 1H, *J* = 8.2 Hz), 4.86--4.90 (m, 4H), 5.48 (s, 1H), 6.99--7.18 (m, 13H), 7.57 (m, 2H); ^13^C NMR (126 MHz, C~6~D~6~) δ 23.6, 67.0, 69.6, 69.6, 72.5, 84.9, 102.0, 126.9, 128.5, 128.7, 128.9, 136.20, 138.7; ^31^P NMR (202 MHz, C~6~D~6~) δ 0.21.

### 2-*C*-Ethyl-[d]{.smallcaps}-erythritol 4-Phosphate, Ammonium Salt (**EEP**) {#sec3.1.8}

Compound **7** (410 mg, 0.82 mmol) was hydrogenated (1 atm, −10 °C) using 10% Pd/C (82 mg) in MeOH (10 mL) for 30 min. The mixture was filtered and solvent evaporated to give 270 mg of an oil. The oil was treated with 20% Pd(OH)~2~/C (130 mg) in MeOH (7 mL) at 1 atm of H~2~ for 24 h. The catalyst was removed by filtration; solvent was evaporated; and the residue was purified by chromatography (silica gel, acetonitrile/isopropyl alcohol/10% aq. NH~4~OH 1:1:1). Finally, lyophilization of the eluate afforded 205 mg (94%) of an amorphous solid: TLC *R*~f~ 0.24 (acetonitrile/isopropyl alcohol/10% aq. NH~4~OH 1:1:1); ^1^H NMR (500 MHz, D~2~O) δ 0.88 (t, 3H, *J* = 7.6 Hz), 1.61 (AB part of ABX, 2H), 3.59 and 3.60 (ABq, 2H, *J* = 11.9 Hz), 3.81--3.85 (m, 2H), 3.93--3.98 (m, 1H); ^13^C NMR (126 MHz, D~2~O) δ 27.8, 65.9, 67.4, 76.1, 78.8; ^31^P NMR (202 MHz, D~2~O) δ 4.94.

### (*Z*)-*ter*t-Butyl-dimethyl-\[2-methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-enyloxy\]silane (**9**) {#sec3.1.9}

3,4-Dihydro-2*H*-pyran (126 mg, 1.5 mmol) and PPTS (25 mg, 0.1 mmol) were added to a solution of alcohol **8**([@ref16]) (217 mg, 1 mmol) in CH~2~Cl~2~ at rt. After stirring overnight, the solution was washed with saturated NaHCO~3~ (10 mL) and extracted with CH~2~Cl~2~ (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~. The solvent was removed at reduced pressure, and the residue was chromatographed on silica gel with gradient elution by hexanes/ethyl acetate (0% to 10% ethyl acetate) to give 295 mg (98%) of a colorless oil: *R*~f~ 0.87 (hexanes:ethyl acetate 1:1); ^1^H NMR (CDCl~3~, 300 MHz) 0.07 (6H, s), 0.90 (9H, s), 1.49--1.85 (9H, m), 3.47--3.54 (1H, m), 3.83--3.91 (1H, m), 3.99--4.06 (1H, s), 4.18 (2H, s), 4.21--4.28 (1H, m), 4.61 (1H, t, *J* = 2.9 Hz), 5.42 (1H, m); ^13^C NMR (CDCl~3~, 75 MHz) −5.3, 18.3, 19.5, 21.0, 25.5, 25.9, 30.6, 61.8, 62.2, 62.9, 97.9, 122.4, 139.7; HRMS (MALDI) calcd for C~16~H~32~O~3~SiNa \[M + Na^+^\] 323.2013, found 323.2001.

### (*Z*)-2-Methyl-4-(tetrahydro-pyran-2-yloxy)-but-2-en-1-ol (**10**) {#sec3.1.10}

A solution of 1 M TBAF in THF (4.36 mL, 4.36 mmol) was added dropwise to a solution of **9** (437 mg, 1.45 mmol) in THF (15 mL) at 0 °C. The temperature was allowed to rise to rt. After stirring for 3 h, the reaction was quenched with brine (15 mL). The layers were separated, and the aqueous layer was extracted with ether (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~. The solvent was removed at reduced pressure, and the residue was chromatographed on silica gel with gradient elution by hexanes/ethyl acetate (0% to 30% ethyl acetate) to give 315 mg (94%) of a colorless oil: *R*~f~ 0.25 (hexanes:ethyl acetate 1:1); ^1^H NMR (CDCl~3~, 300 MHz) 1.52--1.86 (9H, m), 2.59 (1H, broad s), 3.50--3.57 (1H, m), 3.82--3.90 (1H, m), 4.00--4.27 (4H, s), 4.70 (1H, t, *J* = 2.9 Hz), 5.51 (1H, t, *J* = 7.2 Hz); ^13^C NMR (CDCl~3~, 75 MHz) 19.1, 21.9, 25.3, 30.4, 61.4, 62.0, 62.4, 97.0, 123.3, 141.0; HRMS (MALDI) calcd for C~10~H~18~O~3~Na \[M + Na^+^\] 209.1148, found 209.1158.

### (*Z*)-2-\[2-Methyl-4-(tetrahydropyran-2-yloxy)but-2-enyl\]isoindole-1,3-dione (**11**) {#sec3.1.11}

A solution of DIAD (223 mg, 1.1 mmol) in THF (1 mL) was added dropwise to a solution of an alcohol **10** (187 mg, 1 mmol), phthalimide (162 mg, 1.1 mmol), and PPh~3~ (289 mg, 1.1 mmol), in THF (4 mL) at rt. After stirring overnight, the solvent was removed at reduced pressure. The residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 25% ethyl acetate) to give 241 mg (76%) of a white solid: *R*~f~ 0.63 (hexanes:ethyl acetate 1:1); mp = 77--78 °C; ^1^H NMR (CD~2~Cl~2~, 300 MHz) 1.48--1.83 (9H, m), 3.47--3.54 (1H, m), 3.83--3.91 (1H, m), 4.21--4.28 (1H, m), 4.32 (2H, s), 4.38--4.45 (1H, m), 4.65--4.67 (1H, m), 5.53--5.59 (1H, m), 7.70--7.76 (2H, m), 7.80--7.84 (2H, m); ^13^C NMR (CD~2~Cl~2~, 75 MHz) 20.1, 21.9, 26.1, 31.3, 38.8, 62.7, 63.5, 98.6, 123.6, 126.7, 132.6, 134.3, 134.5, 168.7; HRMS (MALDI) calcd. for C~18~H~21~NO~4~Na \[M + Na^+^\] 338.1363, found 338.1357.

### (*Z*)-2-Methyl-4-(tetrahydropyran-2-yloxy) But-2-enylamine (**12**) {#sec3.1.12}

To a solution of phthalimide **11** (318 mg, 1 mmol) in EtOH (9 mL) was added hydrazine hydrate (150 mg, 3 mmol) in EtOH (1 mL). The solution was warmed to 50 °C, stirred for 30 min, and heated at reflux for 2 h. The solution was cooled and filtered. The filter cake was washed with EtOH (3 × 10 mL), and solvent was removed at reduced pressure. The residue was dissolved in ether (20 mL), and 1 M NaOH (5 mL) was added to adjust the pH to 12. The aqueous layer was saturated with NaCl and extracted with ether. The combined organic extracts were dried over Na~2~SO~4~. The solvent was removed at reduced pressure to give 144 mg (77%) of a yellow liquid, which was used in the next step without further purification: ^1^H NMR (CD~2~Cl~2~, 300 MHz) 1.1.40--1.81 (11H, m), 3.23 (2H, s), 3.44--3.50 (1H, m), 3.78--3.86 (1H, m), 3.95--4.02 (1H, m), 4.15--4.21 (1H, m), 4.57--4.60 (1H, m), 5.34--5.41 (1H, m); ^13^C NMR (CD~2~Cl~2~, 75 MHz) 20.1, 22.1, 26.1, 31.2, 42.9, 62.6, 63.1, 98.2, 122.6, 142.4.

### (*Z*)-\[2-Methyl-4-(tetrahydropyran-2-yloxy) but-2-enyl\] Carbamic Acid *tert*-Butyl Ester (**13**) {#sec3.1.13}

Amine **12** (600 mg, 3.24 mmol) was dissolved in *i*PrOH/H~2~O (3:1, v/v, 140 mL), and solid Na~2~CO~3~ (3.24 g) was added. The solution was cooled to 0 °C. A solution of di-*tert*-butyl dicarbonate (1.46 g, 6.48 mmol) in *i*PrOH/H~2~O (3:1, v/v, 20 mL) was added. The mixture was stirred overnight at rt. *i*PrOH was removed at reduced pressure, and the aqueous layer was extracted with ether. The combined organic extracts were dried over Na~2~SO~4~. The solvent was removed at reduced pressure, and the residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 15% ethyl acetate) to give 640 mg (69%) of a colorless oil: *R*~f~ 0.56 (hexanes:ethyl acetate 1:1); ^1^H NMR (CDCl~3~, 300 MHz) 1.26--1.89 (18H, m2), 3.49--3.56 (1H, m), 3.78 (2H, d, *J* = 5.9 Hz), 3.83--3.90 (1H, m), 4.00--4.07 (1H, m), 4.21--4.27 (1H, m), 4.63--4.65 (1H, m), 4.75 (1H, broad s), 5.51 (1H, t, *J* = 7 Hz); ^13^C NMR (CDCl~3~, 75 MHz) 19.4, 22.0, 25.34, 28.3, 30.5, 40.8, 62.2, 62.7, 79.1, 97.7, 124.1, 138.0, 156.0; HRMS (MALDI) calcd for C~15~H~27~NO~4~Na \[M + Na^+^\] 308.1828, found 308.1828.

### (*Z*)-(4-Hydroxy-2-methylbut-2-enyl)carbamic Acid *tert*-Butyl Ester (**14**) {#sec3.1.14}

PPTS (25 mg, 0.1 mmol) was added to the solution of **13** (286 mg, 1 mmol) in EtOH (10 mL). The solution was stirred at 55 °C for 1 h and allowed to cool to rt. The solvent was removed at reduced pressure, and the residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 40% ethyl acetate) to give 198 mg (98%) of a colorless oil: *R*~f~ 0.56 (hexanes:ethyl acetate 1:1); ^1^H NMR (CDCl~3~, 300 MHz) 1.43 (9H, s), 1.76 (3H, t, *J* = 0.7 Hz), 3.19 (1H, broad s), 3.74 (2H, dd, *J*~1~ = 5.6 Hz, *J*~2~ = 0.7 Hz), 4.14 (2H, t, *J* = 6.5 Hz), 4.91 (1H, broad s), 5.67 (1H, t, *J* = 7.3 Hz); ^13^C NMR (CDCl~3~, 75 MHz) 21.6, 28.3, 40.7, 57.5, 79.9, 127.2, 136.2, 156.2; HRMS (MALDI) calcd for C~10~H~19~NO~3~Na \[M + Na^+^\] 224.1263, found 224.1268.

### (*Z*)-\[4-(Bisbenzyloxyphosphoryloxy)-2-methylbut-2-enyl\]carbamic Acid *tert*-Butyl Ester (**15**) {#sec3.1.15}

A solution of I~2~ (609 mg, 2.4 mmol) in CH~2~Cl~2~ (30 mL) was added to a solution of P(OBn)~3~ in CH~2~Cl~2~ (20 mL) at −40 °C. The mixture was stirred for 15 min, and the cooling bath was removed. After 30 min the solution became colorless and was cannulated to a mixture of alcohol **14** (200 mg, 1.2 mmol) and pyridine (570 mg, 7.2 mmol) in CH~2~Cl~2~ (30 mL) at −40 °C over 30 min. After the addition was complete, the mixture was stirred for 1 h at rt, and the solvents were removed at reduced pressure. The residue was dissolved in ether (50 mL) and washed with 0.3 M KHSO~4~ (30 mL), satd. NaHCO~3~ (30 mL), and brine (30 mL). The combined organic extracts were dried over Na~2~SO~4~, and solvent was removed at reduced pressure. The residue was chromatographed on silica gel with gradient elution by hexanes/ethyl acetate (0% to 30% ethyl acetate) to give 320 mg (70%) of a colorless oil: *R*~f~ 0.48 (hexanes:ethyl acetate 1:1); ^1^H NMR (CDCl~3~, 300 MHz) 1.44 (9H, s), 1.74 (3H, t, *J* = 0.6 Hz), 3.71 (2H, d, *J* = 6.2 Hz), 4.54 (2H, dd, *J*~1~ = 7.7 Hz, *J*~2~ = 2.3 Hz), 4.94 (1H, broad s), 5.02 (2H, dd, *J*~1~ = 6.5 Hz, *J*~2~ = 1.7 Hz), 5.43 (1H, t, *J* = 7 Hz), 7.35 (10H, s); ^13^C NMR (CDCl~3~, 75 MHz) 21.8, 28.4, 40.4, 63.4, 63.4, 69.1, 69.2, 121.8, 121.9, 127.9, 128.0, 128.5, 128.6, 128.7, 135.8, 135.9, 140.5, 156.1; ^31^P NMR (CDCl~3~, 125 MHz) 0.68; HRMS (MALDI) calcd for C~24~H~32~NO~6~PNa \[M + Na^+^\] 484.1865, found 484.1872.

### 1-Deoxy-1-boc-amino-4-(dibenzyloxyphosphoryloxy)-3-methyl-[d]{.smallcaps}-erythritol (**16**) {#sec3.1.16}

A solution of AD mix β (3.14 g), NaHCO~3~ (565 mg, 6.73 mmol), and CH~3~SO~2~NH~2~ (160 mg, 1.68 mmol) in *t*BuOH:H~2~O (1:1 v/v, 12 mL) was cooled to 0 °C, and alkene **15** (250 mg, 0.56 mmol) was added. The mixture was stirred overnight at 0 °C before Na~2~SO~3~ (3.36 g) was added. The temperature was allowed to rise to rt as the solution was stirred for 1 h. The layers were separated, and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 20 mL). The combined organic extracts were dried over Na~2~SO~4~, and solvent was removed at reduced pressure. The residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 30% ethyl acetate) to give 172 mg (64%) of a colorless oil: *R*~f~ 0.25 (hexanes:ethyl acetate 1:1); \[α\]~D~^20^ + 11.7 (*c* 0.75, CHCl~3~); ^1^H NMR (CDCl~3~, 300 MHz) 0.04 (3H, s), 1.43 (9H, s), 2.96--3.05 (2H, m), 3.33--3.40 (1H, m), 3.68--3.72 (1H, m), 3.98--4.07 (1H, m), 4.33 (1H, t, *J* = 10.5 Hz), 4.69 (2H, s), 4.98--5.09 (4H, m), 5.36 (1H, broad s), 7.34 (10H, s); ^13^C NMR (CDCl~3~, 75 MHz) 19.7, 28.3, 48.4, 69.3, 69.4, 69.6, 69.7, 73.3, 73.8, 80.4, 128.1, 128.1, 128.6 135.2, 135.6, 158.3; ^31^P NMR (CDCl~3~, 125 MHz) 0.72; HRMS (MALDI) calcd for C~24~H~34~NO~8~PNa \[M + Na^+^\] 518.1909, found 518.1909.

### 1-Amino-3-methyl-[d]{.smallcaps}-erythritol-4-phosphate, Ammonium Salt (**NMEP**) {#sec3.1.17}

A suspension of **16** (100 mg, 0.2 mmol) and Pd/C (8 mg) in CH~3~OH (5 mL) was flushed with H~2~ and was allowed to stir for 1 h under a balloon of H~2~. The mixture was concentrated at reduced pressure. An ^1^H NMR spectrum showed that no benzyl groups remained. The residue was dissolved in CH~3~OH (4 mL), and 3 M HCl (1 mL) was added. After 30 min, the mixture was concentrated at reduced pressure, and the residue was chromatographed on silica eluted with a *i*PrOH:H~2~O:NH~4~OH (6:0.5:2.5 v/v/v) mixture to give 41 mg (89%) of a white solid: *R*~f~ 0.38 (*i*PrOH:H~2~O:NH~4~OH (6:1:3 v/v/v)); \[α\]~D~^20^ + 15.4 (*c* 0.65, D~2~O); ^1^H NMR (D~2~O, 300 MHz) 1.26 (3H, s), 3.07 (1H, d, *J* = 13.2 Hz), 3.25 (1H, d, *J* = 13.2 Hz), 3.75--3.77 (1H, m), 3.81--3.91 (1H, m), 3.97--4.04 (1H, m); ^13^C NMR (D~2~O, 75 MHz) 20.4, 46.2, 64.5, 71.4, 75.8 (*J* = 7 Hz); ^31^P NMR (D~2~O, 125 MHz) 4.20; HRMS (MALDI) calcd for C~5~H~13~NO~6~P \[M -- H^+^\] 214.0486, found 214.0489.

### (2*S*,3*S*)-4-(*tert-*Butyldimethylsilanyloxy)-2,3-dihydroxy-3-methylbutyric Acid Methyl Ester (**18**) {#sec3.1.18}

Alkene **17**([@ref16]) (300 mg, 1.16 mmol) was asymmetrically dihydroxylated following the procedure described for **16**. The residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 15% ethyl acetate) to give 250 mg (73%) of a colorless oil: *R*~f~ 0.14 (hexanes:ethyl acetate 4:1); \[α\]~D~^20^ +26.2 (*c* 1.8, CHCl~3~); ^1^H NMR (CDCl~3~, 300 MHz) 0.09 (6H, s), 0.91 (9H, s), 1.17 (3H, d, *J* = 0.6 Hz), 3.10 (1H, s), 3.34--3.37 (1H, m), 3.48 (1H, d, *J* = 10 Hz), 3.68 (1H, d, *J* = 10 Hz), 3.81 (3H, s), 4.11 (1H, d, *J* = 8 Hz); ^13^C NMR (CDCl~3~, 75 MHz) −5.6, −5.6, 18.3, 19.64, 25.8, 52.5, 68.0, 73.3, 75.0, 173.7; HRMS (MALDI) calcd for C~12~H~26~O~5~SiNa \[M + Na^+^\] 301.1435, found 301.1435.

### (4*S*,5*S*)-5-(*tert*-Butyldimethylsilanyloxymethyl)-2-methoxy-1,3-dioxolane-4-carboxylic Acid Methyl Ester (**19**) {#sec3.1.19}

To a solution of trimethyl orthoformate (291 mg, 2.74 mmol) and diol **18** (200 mg, 0.69 mmol) in CH~2~Cl~2~ (9 mL) was added CSA (16 mg, 0.07 mmol) in CH~2~Cl~2~ (1 mL). After stirring overnight, the solution was washed with saturated NaHCO~3~; the layers were separated; and the aqueous layer was extracted with CH~2~Cl~2~ (3 × 20 mL). The combined organic extracts were dried over Na~2~SO~4~. The solvent was removed at reduced pressure to give 230 mg (100%) of a colorless oil. This material partially decomposed when chromatographed on silica and was used in the next reaction without purification. A small sample was isolated by chromatography for characterization: *R*~f~ 0.63 (hexanes:ethyl acetate 3:2); dr 87:13 (by ^1^H NMR analysis of the orthoester); for major diastereomer ^1^H NMR (CDCl~3~, 300 MHz) 0.02 (6H, s), 0.86 (9H, s), 1.49 (3H, s), 3.34 (3H, s), 3.56 (2H, dd, *J*~1~ = 18 Hz, *J*~2~ = 10.6 Hz), 4.40 (1H, s), 5.88 (1H, s); ^13^C NMR (CDCl~3~, 75 MHz) −5.7, −5.6, 18.3, 22.4, 25.7, 51.6, 52.1, 65.6, 79.0, 84.7, 116.0, 168.5; HRMS (MALDI) calcd for C~14~H~28~O~6~SiNa \[M + Na^+^\] 343.1547, found 343.1558.

### (4*S*,5*S*)-5-\[*tert*-Butyldimethylsilanyloxymethyl)-2-methoxy-5-methyl\[1,3\]dio-xolan-4-yl\]methanol (**20**) {#sec3.1.20}

A solution of 2 M LiBH~4~ in THF (0.6 mL, 1.2 mmol) was added dropwise by a syringe to a solution of **19** (200 mg, 0.6 mmol) in ether (20 mL) at rt. The resulting solution was stirred for 1 h before EtOH (5 mL) and brine (5 mL) were added. The organic layer was separated, and the aqueous layer was extracted with ether (3 × 10 mL). The combined organic extracts were dried over Na~2~SO~4~. The solvent was removed at reduced pressure to give 175 mg (quant) of a colorless oil. This material partially decomposed when chromatographed on silica and was used in the next reaction without purification. A small sample was isolated by chromatography for characterization: *R*~f~ 0.63 (hexanes:ethyl acetate 3:2); dr 87:13 (by ^1^H NMR analysis of the orthoester); for major diastereomer ^1^H NMR (CDCl~3~, 300 MHz) 0.11 (6H, s), 0.91 (9H, s), 1.45 (3H, s), 3.32 (3H, s), 3.71--4.09 (5H, m), 5.67 (1H, s); ^13^C NMR (CDCl3, 75 MHz) −5.7, −5.7, 18.1, 22.8, 25.7, 51.7, 60.3, 65.0, 81.3, 82.6, 114.8; HRMS (FTMS) calcd for C~12~H~25~O~4~Si \[M -- OCH~3~\] 261.1517, found 261.15164.

### (4*S*,5*S*)-5-\[*tert*-Butyldimethylsilanyloxymethyl)-2-methoxy-5-methyl\[1,3\]dio-xolan-4-yl\]methyl *p*-Toluenesulfonate (**21**) {#sec3.1.21}

Alcohol **20** (60 mg, 0.21 mmol) and DMAP (75 mg, 0.62 mmol) were dissolved in CH~2~Cl~2~ (5 mL), and TsCl (78 mg, 0.41 mmol) in CH~2~Cl~2~ (2 mL) was added by syringe. The mixture was allowed to stir overnight. The solvents were removed at reduced pressure, and the residue was chromatographed on silica gel with gradient elution by hexanes/ethyl acetate (0% to 10% ethyl acetate) to give 90 mg (98%) of a colorless oil: *R*~f~ 0.59 (hexanes:ethyl acetate 3:2); dr 87/13 (by ^1^H NMR analysis of the orthoester); \[α\]~D~^20^ +10.2 (*c* 0.9, CHCl~3~); for the major diastereomer ^1^H NMR (CDCl3, 300 MHz) 0.82 (9H, s), 1.34 (3H, s), 2.45 (3H, s), 3.29 (3H, s), 3.32 (1H, d, *J* = 10.5 Hz), 3.50 (1H, d, *J* = 10.5 Hz), 4.10--4.18 (2H, m), 4.33--4.41 (1H, m), 5.68 (1H, s), 7.13 (2H, d, *J* = 8 Hz), 7.80 (2H, d, *J* = 8 Hz); ^13^C NMR (CDCl~3~, 75 MHz) −5.9, −5.7, 17.9, 21.6, 25.6, 51.5, 65.1, 68.4, 79.7, 82.5, 115.4, 128.0, 129.9, 132.7, 144.9; HRMS (FTMS) calcd for C~19~H~31~O~6~SSi \[M -- OCH~3~\] 415.1605, found 415.16047.

### (2*R*,3*S*)-4-(*tert*-Butyldimethylsilanyloxy)-2,3-dihydroxy-3-methylbutyl Tosylate (**22**) {#sec3.1.22}

A solution of **21** (230 mg, 0.54 mmol) in THF (6 mL, 3 M HCl:THF, 1:25) was allowed to stir for 30 min. The mixture was cooled to 0 °C; 6 mL of ammonia in MeOH were added; and the solution was allowed to stir for 15 min at rt. The solvent was removed at reduced pressure, and the residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 30% ethyl acetate) to give 160 mg (76%) of a colorless oil; *R*~*f*~ 0.36 (hexanes:ethyl acetate 1:1); \[α\]~D~^20^ +18.9 (c 1.7, CHCl~3~); ^1^H NMR (CDCl3, 300 MHz) 0.06 (6H, s), 0.88 (9H, s), 1.07 (3H, s), 2.45 (3H, d, *J* = 0.3 Hz), 2.71--2.74 (2H, broad), 3.38 (1H, d, *J* = 10 Hz), 3.67 (1H, d, *J* = 10 Hz), 3.82 (1H, dd, *J*~1~ = 6 Hz, *J*~2~ = 2.5 Hz), 4.09 (1H, dd, *J*~1~ = 8 Hz, *J*~2~ = 2.0 Hz), 4.32 (1H, dd, *J*~1~ = 8.0 Hz, *J*~2~ = 2.5 Hz), 7.36 (2H, d, *J* = 8 Hz), 7.81 (2H, d, *J* = 8 Hz); ^13^C NMR (CDCl~3~, 75 MHz) −5.6, 18.1, 19.0, 21.6, 25.8, 67.6, 72.0, 72.7, 72.9, 128.0, 129.9, 132.6, 145.0; HRMS (FTMS) calcd. for C~18~H~33~O~6~SSi \[M+H^+^\] 405.17616, found 405.17603.

### (2*S*)-1-(*tert*-Butyl-dimethylsilanyloxy)-2-\[(*S*)-1-oxiranyl\]propan-2-ol (**23**) {#sec3.1.23}

To a solution of tosylate **22** (367 mg, 0.91 mmol) in THF (6 mL) at 0 °C was added *t*BuOK (112 mg, 1.0 mmol) in THF (4 mL). The solution was allowed to stir for 1 h at 0 °C; the solvent was removed at reduced pressure; and the residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate to give 196 mg (93%) of a colorless oil: *R*~f~ 0.36 (hexanes:ethyl acetate 1:1); \[α\]~D~^20^ +15.0 (*c* 2.6, CHCl~3~); ^1^H NMR (CDCl~3~, 300 MHz) 0.08 (6H, s), 0.91 (9H, s), 1.18 (3H, s), 2.36 (1H, s), 2.74 (1H, dd, *J*~1~ = 4.0 Hz, *J*~2~ = 1.0 Hz), 2.83 (1H, dd, *J*~1~ = 2.8 Hz, *J*~2~ = 2.2 Hz), 3.01 (1H, dd, *J*~1~ = 2.8 Hz, *J*~2~ = 1.0 Hz), 3.51 (1H, d, *J* = 9.8 Hz), 3.61 (1H, d, *J* = 9.8 Hz); ^13^C NMR (CDCl~3~, 75 MHz) −5.6, 18.2, 20.9, 25.8, 44.0, 55.7, 68.4, 70.2; HRMS (FTMS) calcd for C~11~H~25~O~3~Si \[M + H^+^\] 233.15675, found 233.15712.

### (2*S*)-2-\[(*S*)-1-Oxiranyl\]propane-1,2-diol (**24**) {#sec3.1.24}

The complex Et~3~N--3HF (1.1 g, 6.9 mmol) in THF (2 mL) was added dropwise to a solution of silyl ether **23** (160 mg, 0.69 mmol) in THF (8 mL) at rt. After stirring overnight, Et~3~N (5 mL) was added; solvent was removed at reduced pressure, and the residue was chromatographed on silica with gradient elution by hexanes/ethyl acetate (0% to 30% ethyl acetate) to give 68 mg (83%) of a colorless oil: *R*~f~ 0.29 (hexanes:ethyl acetate 1:1); er 17:1 (as determined by ^19^F NMR analysis of the Mosher's ester); \[α\]~D20~ +17.4 (*c* 0.65, CHCl~3~); ^1^H NMR (CDCl~3~, 300 MHz) 1.26 (3H, s), 2.36 (1H, broad), 2.50 (1H, s), 2.81--2.88 (2H, m), 3.04 (1H, dd, *J*~1~ = 2.9 Hz, *J*~2~ = 1.1 Hz), 3.49--3.62 (2H, m); ^13^C NMR (CDCl~3~, 75 MHz) 22.3, 44.5, 56.6, 67.2, 70.3; HRMS (FTMS) calcd for C~5~H~9~O~2~ \[M -- OH\] 101.05971, found 101.06000.

### 3-Methyl-[d]{.smallcaps}-erythritol-4-thiolophosphate, Ammonium Salt (**MESP**) {#sec3.1.25}

To epoxide **50** (34 mg, 0.29 mmol) was added trisodium thiophosphate (126 mg, 0.32 mmol) in H~2~O (0.6 mL) at rt. The solution was allowed to stir overnight and then lyophilized. The residue was chromatographed on cellulose to give 25 mg of a white powder (32%): *R*~f~ 0.42 (*i*PrOH:H~2~O:NH~4~OH 6/1/3 v/v/v); \[α\]~D~^20^ +16.3 (*c* 0.53, D~2~O); ^1^H NMR (D~2~O, 300 MHz) 1.09 (3H, s), 2.67--2.78 (1H, m), 2.96--3.05 (1H, m), 3.51 (2H, dd, *J*~1~ = 17.2 Hz, *J*~2~ = 11.8 Hz), 3.72 (1H, dd, *J*~1~ = 8.4 Hz, *J*~2~ = 2.2 Hz); ^13^C NMR (D~2~O, 75 MHz) 17.7, 31.5 (*J* = 3 Hz), 66.7, 75.0, 75.5 (*J* = 3 Hz); ^31^P NMR (D~2~O, 125 MHz) 17.82; HRMS (FTMS) calcd for C~5~H~14~O~6~PS \[M + H^+^\] 233.02432, found 233.02482.

Product Studies {#sec3.2}
---------------

### TLC Analysis {#sec3.2.1}

Enzymatic reactions were carried out at 37 °C in 0.1 mM Tris·HCl buffer, pH 7.6, containing 5 mM DTT, 10 mM MgCl~2~, 150 μM **CTP**, 150 μM **ATP**, 500 μM **MEP** (racemic), [d]{.smallcaps}-**EP** or [d]{.smallcaps}-**MTP** or [d]{.smallcaps}-**EEP**, 4.8 μM IspDF, 6.2 μM IspE (where applicable) in a final volume of 50 μL. \[^32^P\]NTPs were diluted from 5 mM stock solutions of 40 μCi/μmol \[α-^32^P\]**CTP** and 320 μCi/μmol \[γ-^32^P\]**ATP**. Reactions were initiated by addition of CTP. After 1 h, the reactions were quenched with 60 μL of methanol and were put on ice. TLC analysis (Polygram Sil N-HR; Macherey and Nagel) was performed by spotting 4.5 μL of the reaction mixture and developing the plates with *n*-propanol/ethyl acetate/H~2~O (6:1:3, v/v/v). Radioactivity was quantified by phosphorimaging.

### LC--MS Analysis {#sec3.2.2}

LC--MS analyses for incubations with **EP**, **EEP**,**NMEP**, and **MESP** similar to those described in the TLC analyses were carried out on a 1 mM scale using unlabeled **CTP** (0.75 mM), unlabeled **ATP** (0.75 mM), IspDF (4.8 μM), and IspE (6.2 μM). The reactions were incubated for 1 h and were centrifuged through a membrane (10 kDa cutoff) to remove the enzymes. Products were detected by negative-ion electrospray LC--MS using a Phenomex Prodigy 5 μ ODS(3) 100A (250 × 4.60 mm 5 μM) column eluted with 20 mM *N*,*N*′-dimethylhexylamine in 10% methanol, pH 7.0, adjusted with formic acid (Buffer A) and 2 mM *N*,*N*′-dimethylhexylamine in 50% methanol, pH 7.0 (Buffer B), as previously described.^[@ref4]^

### Time Course Studies {#sec3.2.3}

A solution of 500 μM **EP** (or **EEP**), 4.8 μM IspDF, and 6.2 μM IspE in 0.1 M Tris·HCl buffer, pH 7.6 (37 °C), 10 mM MgCl~2~, containing 5 mM DTT, in a final volume of 100 μL was preincubated for 10 min at 37 °C. γ-\[^32^P\]**ATP** (150 μM) and α-\[^32^P\]**CTP** (150 μM, 40 μCi/μmol) were added sequentially to initiate the reaction. At various times, 6 μL portions of the mixture were removed and quenched with 6 μL of methanol. After 61 min, an additional 2 μg portions of each enzyme were added to the reaction mixture.

### Inhibition Studies with **MTP** {#sec3.2.4}

A solution of 500 μM **MEP** and 0.36 μM IspDF in 0.1 M Tris·HCl buffer, pH 7.6 (37 °C), containing 5 mM DTT and 10 mM MgCl~2~ was preincubated for 10 min. α-\[^32^P\]**CTP** (150 μM) was added to initiate the reaction. At various times, 6 μL portions of the mixture were removed and quenched with 6 μL of methanol. The samples were analyzed by TLC.^[@ref4]^ The same experiment was performed except **MTP** was added to 5 mM. No change was seen in the rate of formation of **CDP--ME**.

Additional figures for time course TLC and LC--MS chromatograms. NMR spectra. This material is available free of charge via the Internet at <http://pubs.acs.org/>
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